The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found.
drug Ozempic and the weight-loss medication Wegovy -- had a nearly 14% decrease in their body weight after 68 weeks, compared with 3% of people given a placebo, results showed. The trial was funded by Novo Nordisk, the drug company that makes semaglutide.Two-thirds of the patients were randomly assigned to receive semaglutide, while the remaining third got a placebo.
Bob Carter, deputy director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, told the New York Times. “They had an almost 50% reduction in their knee painSemaglutide patients also had nearly twice the improvement in physical function scores, 12 points versus 6.5 points for those talking placebo, the study says.“The good news is that surgery works for most people,” Dr. Carter said. “The bad news is that it is hugely expensive.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy vs. Ozempic: How the 2 Drugs Are DifferentWegovy and Ozempic use the same semaglutide medication but at different doses. Here's what to know about Wegovy vs. Ozempic.
Read more »
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copiesThe Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make…
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »